POM-VPS
Prescription Required
Moxisolv LA 100 mg/ml Solution for Injection for Cattle
Active ingredient: Moxidectin
Form
Injection
Species
Cattle
Manufacturer
Bimeda Animal Health Limited
VMD MA No.
50146/5001
What it's used for
Adult and immature respiratory tract nematode: Dictyocaulus viviparus Warble grubs (migrating larvae): Hypoderma bovis Hypoderma lineatum Lice: Linognathus...
Full indications, dosage and side effects ↓The prescription itself has a price. See what practices near you charge for a consultation and the written prescription fee.
Paying less for Moxidectin
-
1
Ask your vet for a written prescription
They must provide one on request. Under the CMA Order the fee is capped at £21 from 2027.
-
2
Fill it at a registered online retailer
The CMA found online pharmacies 50–60% cheaper than practice dispensing on common medicines — typically £200–£300 a year.
Done — we'll email you when prices land.
Prescription required
Your vet must provide a written prescription on request. You can then purchase from any licensed online retailer.
Clinical information
Moxisolv LA 100 mg/ml Solution for Injection for Cattle — SPC Details
Source: VMD Summary of Product Characteristics (SPC). Last updated 27 Mar 2026.
Adult and immature respiratory tract nematode:
Dictyocaulus viviparus
Warble grubs (migrating larvae):
Hypoderma bovis
Hypoderma lineatum
Lice:
Linognathus vituli
Haematopinus eurysternus
Solenopotes capillatus
Bovicola bovis (reduction of infestation)
Mange mites:
Sarcoptes scabiei
Psoroptes ovis
Chorioptes bovis (reduction of infestation)
Moxidectin has a persistent action and protects cattle for a certain duration against
infection or re-infection with the following parasites for the period indicated:
Species:Protection period
(days):
Dictyocaulus viviparus120Ostertagia ostertagi 120Haemonchus placei 90Oesophagostomum
radiatum
150Trichostrongylus axei 90Linognathus vituli 133
The veterinary medicinal product is effective against Hypoderma larvae at the time of
treatment but its persistent activity against has not been evaluated. If the
veterinary medicinal product is given before the end of the fly season complimentary
treatment with a product effective against Hypoderma
Persistent efficacy periods have not been established for parasite species other than
those included in the above list. Therefore, re-infection of animals on pasture
contaminated by parasites other than these remains possible before the end of the
90-day minimum persistency period demonstrated for specific species.
Dictyocaulus viviparus
Warble grubs (migrating larvae):
Hypoderma bovis
Hypoderma lineatum
Lice:
Linognathus vituli
Haematopinus eurysternus
Solenopotes capillatus
Bovicola bovis (reduction of infestation)
Mange mites:
Sarcoptes scabiei
Psoroptes ovis
Chorioptes bovis (reduction of infestation)
Moxidectin has a persistent action and protects cattle for a certain duration against
infection or re-infection with the following parasites for the period indicated:
Species:Protection period
(days):
Dictyocaulus viviparus120Ostertagia ostertagi 120Haemonchus placei 90Oesophagostomum
radiatum
150Trichostrongylus axei 90Linognathus vituli 133
The veterinary medicinal product is effective against Hypoderma larvae at the time of
treatment but its persistent activity against has not been evaluated. If the
veterinary medicinal product is given before the end of the fly season complimentary
treatment with a product effective against Hypoderma
Persistent efficacy periods have not been established for parasite species other than
those included in the above list. Therefore, re-infection of animals on pasture
contaminated by parasites other than these remains possible before the end of the
90-day minimum persistency period demonstrated for specific species.
Dosage is 1.0 mg moxidectin per kg bodyweight (equivalent to 0.5 ml of the
veterinary medicinal product per 50 kg bodyweight), given by a single subcutaneous
injection in the ear using an 18 gauge, 25 – 40 mm hypodermic needle. The 50 ml
vial stoppers must not be broached more than 30 times, and the 200 ml vial stoppers
must not be punctured more than 50 times. Use automatic syringe equipment for the
200 ml fill size.
Shake well before use.
Underdosing could result in ineffective use and may favour resistance development.
To ensure a correct dosage, body weight should be determined as accurately as
possible. If animals are to be treated collectively, reasonably homogenous groups
should be set up, and all animals of a group should be dosed at the rate
corresponding to the heaviest one.
Accuracy of the dosing device should be thoroughly checked.
AN: 01922/2025 and 01923/2025
The injection should be given subcutaneously in the loose tissues on the dorsal
surface of the ear, just distal to the distal edge of the auricular cartilage.
The dorsal (outer) surface of the ear should first be cleansed with antiseptic and
allowed to briefly air dry. Palpate the edge of the auricular cartilage closest to the
head, on the dorsal (hairy) surface of the ear. From this landmark, taking care to
avoid blood vessels (artery, vein), the needle should be inserted subcutaneously
starting at a point approximately 3 to 3.5 cm distal to this edge (away from the head),
and directed towards the base of the ear, and the needle advanced to the hub. At this
point, gently aspirate the syringe to confirm that the needle is not in a blood vessel.
Upon injection, the resulting depot should reside just distal to the edge of the
auricular cartilage.
Following administration, the needle is withdrawn from the skin as pressure is applied
for several seconds with the thumb at the point of insertion.
Due to the long lasting protection against Dictyocaulus viviparus and the stomach
worms, Ostertagia ostertagiHaemonchus placei, a single treatment with the
formulation at turn-out helps control parasitic bronchitis (lungworm) and parasitic
gastro-enteritis throughout the grazing season by reducing the build-up of infective
larvae on pasture associated with these parasites.
Diagram:
•
3.5 cm (1.5 inches) distal to the distal
edge of the auricular cartilage
•
steady the ear.
•
18-gauge x 1inch needle.
•
just distal to the distal edge of the
auricular cartilage.
•
insertion as the needle is withdrawn
from the skin to help seal the
opening.
AN: 01922/2025 and 01923/2025
veterinary medicinal product per 50 kg bodyweight), given by a single subcutaneous
injection in the ear using an 18 gauge, 25 – 40 mm hypodermic needle. The 50 ml
vial stoppers must not be broached more than 30 times, and the 200 ml vial stoppers
must not be punctured more than 50 times. Use automatic syringe equipment for the
200 ml fill size.
Shake well before use.
Underdosing could result in ineffective use and may favour resistance development.
To ensure a correct dosage, body weight should be determined as accurately as
possible. If animals are to be treated collectively, reasonably homogenous groups
should be set up, and all animals of a group should be dosed at the rate
corresponding to the heaviest one.
Accuracy of the dosing device should be thoroughly checked.
AN: 01922/2025 and 01923/2025
The injection should be given subcutaneously in the loose tissues on the dorsal
surface of the ear, just distal to the distal edge of the auricular cartilage.
The dorsal (outer) surface of the ear should first be cleansed with antiseptic and
allowed to briefly air dry. Palpate the edge of the auricular cartilage closest to the
head, on the dorsal (hairy) surface of the ear. From this landmark, taking care to
avoid blood vessels (artery, vein), the needle should be inserted subcutaneously
starting at a point approximately 3 to 3.5 cm distal to this edge (away from the head),
and directed towards the base of the ear, and the needle advanced to the hub. At this
point, gently aspirate the syringe to confirm that the needle is not in a blood vessel.
Upon injection, the resulting depot should reside just distal to the edge of the
auricular cartilage.
Following administration, the needle is withdrawn from the skin as pressure is applied
for several seconds with the thumb at the point of insertion.
Due to the long lasting protection against Dictyocaulus viviparus and the stomach
worms, Ostertagia ostertagiHaemonchus placei, a single treatment with the
formulation at turn-out helps control parasitic bronchitis (lungworm) and parasitic
gastro-enteritis throughout the grazing season by reducing the build-up of infective
larvae on pasture associated with these parasites.
Diagram:
•
3.5 cm (1.5 inches) distal to the distal
edge of the auricular cartilage
•
steady the ear.
•
18-gauge x 1inch needle.
•
just distal to the distal edge of the
auricular cartilage.
•
insertion as the needle is withdrawn
from the skin to help seal the
opening.
AN: 01922/2025 and 01923/2025
Do not use in animals less than 100 kg bodyweight or greater than 500 kg.
Do not use the veterinary medicinal product intravascularly. Intravascular injection
may result in ataxia, paralysis, convulsions, collapse and death. To prevent any
AN: 01922/2025 and 01923/2025
intravascular injection, carefully follow the administration procedure described in item
“Amounts to be administered and administration route”.
Do not use in cases of hypersensitivity to the active substance or to any of the
excipients.
Do not use the veterinary medicinal product intravascularly. Intravascular injection
may result in ataxia, paralysis, convulsions, collapse and death. To prevent any
AN: 01922/2025 and 01923/2025
intravascular injection, carefully follow the administration procedure described in item
“Amounts to be administered and administration route”.
Do not use in cases of hypersensitivity to the active substance or to any of the
excipients.
Cattle
Rare
(1 to 10 animals / 10,000 animals treated):
Injection site swelling
1,3
,
Depression,
Ataxia
Very rare
(<1 animal / 10,000 animals treated,
including isolated reports):
Hypersensitivity reaction
Injection site abscess
2,3
Immediate or delayed. The frequency tends to be higher in the heavier animals.
Swellings may further develop into abscesses (approx. 1% of cases).
These side effects generally disappear without treatment, within 14 days after
administration, some may persist for up to 5 weeks in a number of animals (<5%)
and in very rare occasions longer.
Symptomatic treatment should be applied.
Reporting adverse events is important. It allows continuous safety monitoring of a
veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to
either the marketing authorisation holder or its local representative or the national
competent authority via the national reporting system. See the package leaflet for
respective contact details.
Rare
(1 to 10 animals / 10,000 animals treated):
Injection site swelling
1,3
,
Depression,
Ataxia
Very rare
(<1 animal / 10,000 animals treated,
including isolated reports):
Hypersensitivity reaction
Injection site abscess
2,3
Immediate or delayed. The frequency tends to be higher in the heavier animals.
Swellings may further develop into abscesses (approx. 1% of cases).
These side effects generally disappear without treatment, within 14 days after
administration, some may persist for up to 5 weeks in a number of animals (<5%)
and in very rare occasions longer.
Symptomatic treatment should be applied.
Reporting adverse events is important. It allows continuous safety monitoring of a
veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to
either the marketing authorisation holder or its local representative or the national
competent authority via the national reporting system. See the package leaflet for
respective contact details.
Unnecessary use of antiparasitics or use deviating from the instructions given in the
SPC may increase the resistance selection pressure and lead to reduced efficacy.
The decision to use the product should be based on confirmation of the parasitic
species and burden, or of the risk of infestation based on its epidemiological features,
for each herd.
Repeated use for an extended period, particularly when using the same class of
substance, increases the risk of resistance development. Within a herd,
maintenance of susceptible refugia is essential to reduce that risk. Systematically
applied interval-based treatment and treatment of a whole herd should be avoided.
Instead, if feasible, only selected individual animals or subgroups should be treated
(targeted selective treatment). This should be combined with appropriate husbandry
and pasture management measures. Guidance for each specific herd should be
sought from the responsible veterinarian.
Partial cross-resistance between ivermectin and moxidectin has been reported in
nematode parasites. Cases of resistance to moxidectin have been reported in
Cooperia, Ostertagia, Oesophagostomum and Trichuris genera of gastrointestinal
nematode parasites of cattle and in Psoroptes mites, in the EU and elsewhere.
The use of this product should take into account local information about susceptibility
of the target parasites, where available.
It is recommended to further investigate cases of suspected resistance, using an
appropriate diagnostic method (e.g. Faecal Egg Count Reduction Test (FECRT)).
Confirmed resistance should be reported to the marketing authorisation holder or to
the competent authority.
Special precautions for safe use in the target species:
In order to prevent abscesses, a strict aseptic technique is recommended. The
veterinary medicinal product has been formulated specifically for subcutaneous
injection in dorsal surface of the ear of cattle and must not be given by any other
route of administration or to any other species.
To avoid possible secondary reactions by the death of Hypoderma larvae in the spine
or the oesophagus of animals, it is recommended to administer a product effective
against larvae after the end of fly activity and before the larvae reach
their resting sites. Consult your veterinary surgeon on the correct timing of this
treatment.
Immunity to nematodes depends on adequate exposure to infection. Although not
normally the case, circumstances could occur in which anthelmintic control measures
AN: 01922/2025 and 01923/2025
might increase the vulnerability of cattle to re-infection. Animals may be at risk
towards the end of their first grazing season, particularly if the season is long, or in
the following year if they move onto heavily contaminated pasture. In such instances,
further control measures may be necessary.
Special precautions to be taken by the person administering the veterinary medicinal
product to animals:
Moxidectin or benzyl alcohol may cause hypersensitivity (allergic reactions). People
with known hypersensitivity to moxidectin or benzyl alcohol should avoid contact with
the veterinary medicinal product.
The veterinary medicinal product may cause skin and eye irritation. Avoid direct
contact with skin and eyes. If skin or eye irritation occur, wash with plenty of water.
Wash hands after use.
Do not smoke, drink or eat while handling the veterinary medicinal product.
Take care to avoid self-injection. In case of accidental self-injection, seek medical
advice and show the package leaflet or the label to the physician.
To the physician:
In case of accidental self-injection treat symptomatically.
Special precautions for the protection of the environment:
Moxidectin fulfils the criteria for a (very) persistent, bioaccumulative and toxic (PBT)
substance; therefore, exposure of the environment to moxidectin must be limited to
the extent possible.
Treatments should be administered only when necessary and should be based on
faecal egg counts or evaluation of the risk of infestation at the animal and/or herd
level.
Like other macrocyclic lactones, moxidectin has the potential to adversely affect non-
target organisms:
•
temporarily reduce the abundance of dung feeding organisms. Following
treatment of cattle with the product, levels of moxidectin that are potentially toxic
to dung fly species may be excreted over a period more than 4 weeks and may
decrease dung fly abundance during that period. It has been established in
laboratory tests that moxidectin may temporarily affect dung beetle
reproduction; however, field studies indicate no long-term effects. Nevertheless,
in case of repeated treatments with moxidectin (as with products of the same
anthelmintic class) it is advisable not to treat animals every time on the same
pasture to allow dung fauna populations to recover.
•
should be used only according to the label instructions. Based on the excretion
profile of moxidectin when administered as the injectable formulation, treated
animals should not have access to watercourses during the 10 days after
treatment.
AN: 01922/2025 and 01923/2025
SPC may increase the resistance selection pressure and lead to reduced efficacy.
The decision to use the product should be based on confirmation of the parasitic
species and burden, or of the risk of infestation based on its epidemiological features,
for each herd.
Repeated use for an extended period, particularly when using the same class of
substance, increases the risk of resistance development. Within a herd,
maintenance of susceptible refugia is essential to reduce that risk. Systematically
applied interval-based treatment and treatment of a whole herd should be avoided.
Instead, if feasible, only selected individual animals or subgroups should be treated
(targeted selective treatment). This should be combined with appropriate husbandry
and pasture management measures. Guidance for each specific herd should be
sought from the responsible veterinarian.
Partial cross-resistance between ivermectin and moxidectin has been reported in
nematode parasites. Cases of resistance to moxidectin have been reported in
Cooperia, Ostertagia, Oesophagostomum and Trichuris genera of gastrointestinal
nematode parasites of cattle and in Psoroptes mites, in the EU and elsewhere.
The use of this product should take into account local information about susceptibility
of the target parasites, where available.
It is recommended to further investigate cases of suspected resistance, using an
appropriate diagnostic method (e.g. Faecal Egg Count Reduction Test (FECRT)).
Confirmed resistance should be reported to the marketing authorisation holder or to
the competent authority.
Special precautions for safe use in the target species:
In order to prevent abscesses, a strict aseptic technique is recommended. The
veterinary medicinal product has been formulated specifically for subcutaneous
injection in dorsal surface of the ear of cattle and must not be given by any other
route of administration or to any other species.
To avoid possible secondary reactions by the death of Hypoderma larvae in the spine
or the oesophagus of animals, it is recommended to administer a product effective
against larvae after the end of fly activity and before the larvae reach
their resting sites. Consult your veterinary surgeon on the correct timing of this
treatment.
Immunity to nematodes depends on adequate exposure to infection. Although not
normally the case, circumstances could occur in which anthelmintic control measures
AN: 01922/2025 and 01923/2025
might increase the vulnerability of cattle to re-infection. Animals may be at risk
towards the end of their first grazing season, particularly if the season is long, or in
the following year if they move onto heavily contaminated pasture. In such instances,
further control measures may be necessary.
Special precautions to be taken by the person administering the veterinary medicinal
product to animals:
Moxidectin or benzyl alcohol may cause hypersensitivity (allergic reactions). People
with known hypersensitivity to moxidectin or benzyl alcohol should avoid contact with
the veterinary medicinal product.
The veterinary medicinal product may cause skin and eye irritation. Avoid direct
contact with skin and eyes. If skin or eye irritation occur, wash with plenty of water.
Wash hands after use.
Do not smoke, drink or eat while handling the veterinary medicinal product.
Take care to avoid self-injection. In case of accidental self-injection, seek medical
advice and show the package leaflet or the label to the physician.
To the physician:
In case of accidental self-injection treat symptomatically.
Special precautions for the protection of the environment:
Moxidectin fulfils the criteria for a (very) persistent, bioaccumulative and toxic (PBT)
substance; therefore, exposure of the environment to moxidectin must be limited to
the extent possible.
Treatments should be administered only when necessary and should be based on
faecal egg counts or evaluation of the risk of infestation at the animal and/or herd
level.
Like other macrocyclic lactones, moxidectin has the potential to adversely affect non-
target organisms:
•
temporarily reduce the abundance of dung feeding organisms. Following
treatment of cattle with the product, levels of moxidectin that are potentially toxic
to dung fly species may be excreted over a period more than 4 weeks and may
decrease dung fly abundance during that period. It has been established in
laboratory tests that moxidectin may temporarily affect dung beetle
reproduction; however, field studies indicate no long-term effects. Nevertheless,
in case of repeated treatments with moxidectin (as with products of the same
anthelmintic class) it is advisable not to treat animals every time on the same
pasture to allow dung fauna populations to recover.
•
should be used only according to the label instructions. Based on the excretion
profile of moxidectin when administered as the injectable formulation, treated
animals should not have access to watercourses during the 10 days after
treatment.
AN: 01922/2025 and 01923/2025
The effects of GABA agonists are increased by moxidectin.
This veterinary medicinal product does not require any special storage conditions.
AN: 01922/2025 and 01923/2025
AN: 01922/2025 and 01923/2025
The effects of GABA agonists are increased by moxidectin.
3.9 Administration routes and dosage
Subcutaneous use.
Dosage is 1.0 mg moxidectin per kg bodyweight (equivalent to 0.5 ml of the
veterinary medicinal product per 50 kg bodyweight), given by a single subcutaneous
injection in the ear using an 18 gauge, 25 – 40 mm hypodermic needle. The 50 ml
vial stoppers must not be broached more than 30 times, and the 200 ml vial stoppers
must not be punctured more than 50 times. Use automatic syringe equipment for the
200 ml fill size.
Shake well before use.
Underdosing could result in ineffective use and may favour resistance development.
To ensure a correct dosage, body weight should be determined as accurately as
possible. If animals are to be treated collectively, reasonably homogenous groups
should be set up, and all animals of a group should be dosed at the rate
corresponding to the heaviest one.
Accuracy of the dosing device should be thoroughly checked.
AN: 01922/2025 and 01923/2025
The injection should be given subcutaneously in the loose tissues on the dorsal
surface of the ear, just distal to the distal edge of the auricular cartilage.
The dorsal (outer) surface of the ear should first be cleansed with antiseptic and
allowed to briefly air dry. Palpate the edge of the auricular cartilage closest to the
head, on the dorsal (hairy) surface of the ear. From this landmark, taking care to
avoid blood vessels (artery, vein), the needle should be inserted subcutaneously
starting at a point approximately 3 to 3.5 cm distal to this edge (away from the head),
and directed towards the base of the ear, and the needle advanced to the hub. At this
point, gently aspirate the syringe to confirm that the needle is not in a blood vessel.
Upon injection, the resulting depot should reside just distal to the edge of the
auricular cartilage.
Following administration, the needle is withdrawn from the skin as pressure is applied
for several seconds with the thumb at the point of insertion.
Due to the long lasting protection against Dictyocaulus viviparus and the stomach
worms, Ostertagia ostertagiHaemonchus placei, a single treatment with the
formulation at turn-out helps control parasitic bronchitis (lungworm) and parasitic
gastro-enteritis throughout the grazing season by reducing the build-up of infective
larvae on pasture associated with these parasites.
Diagram:
•
3.5 cm (1.5 inches) distal to the distal
edge of the auricular cartilage
•
steady the ear.
•
18-gauge x 1inch needle.
•
just distal to the distal edge of the
auricular cartilage.
•
insertion as the needle is withdrawn
from the skin to help seal the
opening.
AN: 01922/2025 and 01923/2025
3.10 Symptoms of overdose (and where applicable, emergency procedures and
antidotes)
Reactions at the injection site have to be expected more frequently and severe
depending on the injected volume. Systemic clinical signs of overdose are consistent
with the mode of action of moxidectin. These clinical signs are manifested as
transient salivation, depression, drowsiness and ataxia 24 to 36 hours post-
treatment. The systemic clinical signs usually disappear within 36 to 72 hours without
treatment. At doses >3 times the recommended dose divided on both ears, the
systemic clinical signs included recumbency, muscle tremor, ruminal tympany and
dehydration, which were resolved after treatment with fluids. The systemic clinical
signs can last for a few days to ten days. There is no specific antidote.
3.11 Special restrictions for use and special conditions for use, including
restrictions on the use of antimicrobial and antiparasitic veterinary
medicinal products in order to limit the risk of development of resistance
Not applicable.
3.12 Withdrawal periods
Meat and offal: 108 days.
Milk: Not authorised for use in animals producing milk for human consumption. Do
not use in pregnant animals which are intended to produce milk for human
consumption within 80 days of expected parturition.
The withdrawal period is based solely on a single injection at the ear site of injection.
3.9 Administration routes and dosage
Subcutaneous use.
Dosage is 1.0 mg moxidectin per kg bodyweight (equivalent to 0.5 ml of the
veterinary medicinal product per 50 kg bodyweight), given by a single subcutaneous
injection in the ear using an 18 gauge, 25 – 40 mm hypodermic needle. The 50 ml
vial stoppers must not be broached more than 30 times, and the 200 ml vial stoppers
must not be punctured more than 50 times. Use automatic syringe equipment for the
200 ml fill size.
Shake well before use.
Underdosing could result in ineffective use and may favour resistance development.
To ensure a correct dosage, body weight should be determined as accurately as
possible. If animals are to be treated collectively, reasonably homogenous groups
should be set up, and all animals of a group should be dosed at the rate
corresponding to the heaviest one.
Accuracy of the dosing device should be thoroughly checked.
AN: 01922/2025 and 01923/2025
The injection should be given subcutaneously in the loose tissues on the dorsal
surface of the ear, just distal to the distal edge of the auricular cartilage.
The dorsal (outer) surface of the ear should first be cleansed with antiseptic and
allowed to briefly air dry. Palpate the edge of the auricular cartilage closest to the
head, on the dorsal (hairy) surface of the ear. From this landmark, taking care to
avoid blood vessels (artery, vein), the needle should be inserted subcutaneously
starting at a point approximately 3 to 3.5 cm distal to this edge (away from the head),
and directed towards the base of the ear, and the needle advanced to the hub. At this
point, gently aspirate the syringe to confirm that the needle is not in a blood vessel.
Upon injection, the resulting depot should reside just distal to the edge of the
auricular cartilage.
Following administration, the needle is withdrawn from the skin as pressure is applied
for several seconds with the thumb at the point of insertion.
Due to the long lasting protection against Dictyocaulus viviparus and the stomach
worms, Ostertagia ostertagiHaemonchus placei, a single treatment with the
formulation at turn-out helps control parasitic bronchitis (lungworm) and parasitic
gastro-enteritis throughout the grazing season by reducing the build-up of infective
larvae on pasture associated with these parasites.
Diagram:
•
3.5 cm (1.5 inches) distal to the distal
edge of the auricular cartilage
•
steady the ear.
•
18-gauge x 1inch needle.
•
just distal to the distal edge of the
auricular cartilage.
•
insertion as the needle is withdrawn
from the skin to help seal the
opening.
AN: 01922/2025 and 01923/2025
3.10 Symptoms of overdose (and where applicable, emergency procedures and
antidotes)
Reactions at the injection site have to be expected more frequently and severe
depending on the injected volume. Systemic clinical signs of overdose are consistent
with the mode of action of moxidectin. These clinical signs are manifested as
transient salivation, depression, drowsiness and ataxia 24 to 36 hours post-
treatment. The systemic clinical signs usually disappear within 36 to 72 hours without
treatment. At doses >3 times the recommended dose divided on both ears, the
systemic clinical signs included recumbency, muscle tremor, ruminal tympany and
dehydration, which were resolved after treatment with fluids. The systemic clinical
signs can last for a few days to ten days. There is no specific antidote.
3.11 Special restrictions for use and special conditions for use, including
restrictions on the use of antimicrobial and antiparasitic veterinary
medicinal products in order to limit the risk of development of resistance
Not applicable.
3.12 Withdrawal periods
Meat and offal: 108 days.
Milk: Not authorised for use in animals producing milk for human consumption. Do
not use in pregnant animals which are intended to produce milk for human
consumption within 80 days of expected parturition.
The withdrawal period is based solely on a single injection at the ear site of injection.
This information is sourced from the official Summary of Product Characteristics (SPC) published by the Veterinary Medicines Directorate (VMD). It is provided for informational purposes only and does not replace professional veterinary advice. Always consult your vet before administering any medication.
Medication costs adding up?
Pet insurance can cover prescription medications. Find the right policy for your pet.
Related Conditions
Same active ingredient
Other Products Containing Moxidectin
These products share the same active ingredient and may be suitable alternatives. Always consult your vet.
Advocate
POM-V
spot-on
Dog
Cat
Advocate 100 mg + 25 mg Spot-on Solution for Medium Dogs (> 4–10 kg)
POM-VElanco Animal Health GmbH
spot-on
Dogs
Advocate 250 mg + 62.5 mg Spot-on Solution for Large Dogs (> 10–25 kg)
POM-VElanco Animal Health GmbH
spot-on
Dogs
Advocate 40 mg + 10 mg Spot-on Solution for Small Dogs (≤ 4 kg)
POM-VElanco Animal Health GmbH
spot-on
Dogs
Advocate 40 mg + 4 mg Spot-on Solution for Small Cats (≤ 4 kg) and Ferrets
POM-VElanco Animal Health GmbH
spot-on
Cats
Ferrets
Advocate 400 mg + 100 mg Spot-on Solution for Extra-Large Dogs (> 25–40 kg)
POM-VElanco Animal Health GmbH
spot-on
Dogs
Alternative options to consider
Retailers we earn a commission from. It costs you nothing and never changes what we show.
The Pharm Pet Co.
Flea & Tick Treatments for Cats
Vet-strength feline flea and tick treatments. Stronghold, Advocate, Frontline and more, dispensed by UK pharmacists.
From £8.99
Shop now
Pharmacy2U
Pet Flea Treatments at Pharmacy2U
Frontline, Advantage and own-brand flea treatments at pharmacy prices. Trusted UK pharmacy since 1999.
From £7.99
Shop now
VetBox
VetBox Flea & Worm Protection for Cats
Vet-founded monthly parasite subscription. Flea, tick and worm protection delivered to your door. Founded by Dr Will Woodley, protecting 30,000+ pets.
From £9.99/month
Shop now
We may earn a small commission if you purchase through these links, at no extra cost to you.
Also in flea-tick
Related Medications
Advantage 100 mg Spot-on Solution for Medium Dogs
AVM-GSLImidacloprid
spot-on
Dogs
Advantage 100 mg Spot-on Solution for Medium Dogs
AVM-GSLImidacloprid
spot-on
Dogs
Advantage 100 Spot-on Solution for Dogs
NFA-VPSImidacloprid
spot-on
Dogs
Advantage 100 Spot-on Solution for Dogs
NFA-VPSImidacloprid
spot-on
Dogs
Advantage 250 mg Spot-on Solution for Large Dogs
AVM-GSLImidacloprid
spot-on
Dogs
Advantage 250 mg Spot-on Solution for Large Dogs
AVM-GSLImidacloprid
spot-on
Dogs
Find cheaper vets near you
Compare vet consultation prices in your area. Save on procedures and get a prescription to buy medications online.